Wolfe Research Assumes BioNTech (BNTX) at Peerperform
- Nasdaq outperforms on Alphabet boost, payrolls data in focus
- Stocks could be in 'panic' mode in 2024, warns JPM's Kolanovic
- Can S&P 500 rally without the Magnificent 7 leading the way? 'Easy' says BofA
- Analysts remain cautious on Chewy as shares drop 10% weak guidance
- AI sentiment toward Google seen improving rapidly after Gemini launch; Shares gain
Wolfe Research analyst Andrew Galler assumes coverage on BioNTech (NASDAQ: BNTX) with a Peerperform rating.
Shares of BioNTech closed at $231.47 yesterday.
You May Also Be Interested In
- UBS Starts Bio-Techne Corp. (TECH) at Buy
- UBS Starts Econpile Holdings Bhd. (ECON:MK) at Neutral
- Wells Fargo Starts Match Group (MTCH) at Equal Weight
Create E-mail Alert Related CategoriesNew Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!